Gilead Sciences Announces Third Quarter 2018 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Gilead Sciences (GILD) PT Raised to $90 at RBC Capital
July 26, 2018 7:58 AM EDTRBC Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $87.00) while maintaining an Outperform rating following results.
Analyst Brian Abraham commented, "With strong HIV sales and HCV stabilizing, GILD seems to be tracking towards steadier earnings base upon which... More
